Jeong, Seung-Hyun
Jang, Ji-Hun
Lee, Yong-Bok
Funding for this research was provided by:
Handok Pharmaceuticals
Article History
Received: 6 July 2023
Accepted: 19 July 2023
First Online: 29 July 2023
Declarations
:
: Clinical studies were conducted in accordance with the Rules of Good Clinical Practice and the revised Declaration of Helsinki for Biomedical Research with Human Subjects. All subjects had no prior history of hypersensitivity or related reactions to steroid drugs and were physically normal. In addition, healthy adults aged 19–55 years have no history of digestive, liver, kidney, cardiovascular, central nervous system, endocrine, or blood diseases in the past and have not been taking any other drugs. All subjects underwent a physical examination, clinical screening, complete blood count, urinalysis, and blood chemistry analysis prior to participation in this clinical study to confirm their physical health. The clinical study protocol used in this study was thoroughly reviewed and approved by the Institutional Review Board of the Institute of Bioequivalence and Bridging Study, Chonnam National University, Gwangju, Republic of Korea (bioequivalence study permit numbers: 100329; 01.28.2010).
: All subjects provided written informed consent prior to their participation in the bioequivalence and pharmacokinetics studies.
: All data were anonymized and participants were informed that the results of this study may be subject to publication and presentation in meetings.
: The authors declare no competing interests.